Skip to main content

Displaying 2701 - 2720 of 4804

Professional Lighting and Sign Management Company of America, Inc., In the Matter of

An association representing electricians agreed to eliminate provisions in its bylaws that the FTC charged limit competition among each association’s members. The FTC alleged that the purpose and effect of the association's bylaws has been to restrain competition by discouraging and restricting competition among PLASMA members. The consent order settling the FTC’s charges requires PLASMA to revise its bylaws, publicize its settlement with the FTC, and implement an antitrust compliance program.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
141 0088

H.I.G. Bayside Debt, et al., In the Matter of

The FTC required Surgery Center Holdings, Inc., known as Surgery Partners, and Symbion Holdings Corporation, to divest Symbion’s ownership interest in an ambulatory surgery center in Orange City, Florida to Dr. Mark W. Hollmann, as part of a settlement resolving charges that Surgery Partners’ $792 million purchase of Symbion would be anticompetitive. Both companies operate a large number of ambulatory surgery centers located throughout the country that sell and provide outpatient surgical services to commercial health plans and commercially insured patients. The proposed merger would have combined the only two multi-specialty ambulatory surgical centers in the Orange City/Deltona area of Florida, and would have left commercial health plans and commercially insured patients there with only one meaningful alternative to Surgery Partners’ outpatient surgical services.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
141 0183
C-4494
Feb24

Examining Health Care Competition

-
The Federal Trade Commission and U.S. Department of Justice, Antitrust Division held a public workshop on February 24-25, 2015, as part of the workshop series, “Examining Health Care Competition,” to...

Schering-Plough Corporation, , In the Matter of

The Commission challenged Schering-Plough’s proposed $41.4 billion acquisition of Merck & Co., and required divestitures to preserve competition in markets for human and animal pharmaceuticals. The proposed consent order requires that Merck sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and that Schering-Plough sell its assets related to significant drugs for nausea and vomiting in humans.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
091 0075
Docket Number
C-4268